Quture International, Inc. / TCLN Announces Successful Completion to QualOptima Product Demonstration
March 27 2012 - 8:00AM
Marketwired
Quture International, Inc. (OTCQB: TCLN) (PINKSHEETS: TCLN) and
Quture, Inc. ("Quture") announced the commencement of the
Demonstration Project for its QualOptima System at Jackson Memorial
Hospital, University of Miami, on September 6, 2011. Today Quture
announces the successful completion of the Demonstration of its new
"transformative and disruptive" tool to enhance clinical
performance to achieve optimal patient outcomes. The
Investigational Review Board of the Miller School of Medicine,
University of Miami, has now approved the protocol to use the
product technology in an academic study. Furthermore, the product
demonstration with InterSystems technology is now complete, moving
the product significantly closer to commercial release.
Landon Feazell, CEO of Quture International, refers to his
original statement of the significance of this accomplishment: "We
are nearing announcement of our first newly enhanced product to
connect true clinical quality with value. We are taking lessons
learned from over 35 years of measuring performance manually and
converting them into an electronic system that can provide
real-time clinical knowledge and insight to doctors, nurses and
hospitals as never before. Our years of developing clinical content
and utilizing a new technology platform will finally achieve its
potential. This is a significant milestone in the evolution of our
now publicly traded company." He added: "Completion of this
project, combined with the project nearing completion at Niagara
Falls Memorial Medical Center, puts us very close to major
announcements with InterSystems."
The Demonstration Project and now the academic study are
designed by Keith A. Candiotti, M.D., Executive Vice-Chair &
Chief Operating Officer, and Vice-Chair, Clinical Research,
Department of Anesthesiology, Jackson Memorial Hospital and
University of Miami Miller Medical School. The demonstration
connects individual patient risk factors with evidence-based
perioperative performance measures compared to patient outcomes.
The impact of compliance on outcomes and costs associated with
extended stays and complications in recovery and beyond for
well-established performance measures in anesthesia connects
clinical quality with outcomes and costs.
"It is truly remarkable to now lead this Company after years of
development of intellectual property and clinical content. These
transformative assets are converging on the remarkable InterSystems
technology platform to derive clinical knowledge solutions," said
Richard Fantozzi, M.D., CEO and Co-Chairman of Quture. "Following
the InterSystems Global Summit just last week in Orlando and now
with this achievement, the months ahead for Quture are very
exciting to not only be part of, but lead. We believe we can solve
the problems of disparate databases and silos of information that
have limited our endeavors for over 35 years of clinical
performance measurement in health care. This is a pivotal juncture
in health care and its impact on the American economy and on the
lives of patients and the professionals devoted to caring for them.
We will be proud to introduce these new tools to accomplish our
mission and bring new capability to the extensive new federal and
national mandates and standards. These accomplishments are
converging to pave the way for other anticipated business
opportunities and reflect our current strategic plans to build
long-term shareholder value."
QUTURE INTERNATIONAL, INC.
Quture International, Inc. is an emerging growth company
positioned to become the leading clinical knowledge company in the
world. The core competence of Quture is clinical performance
enhancement to achieve optimal patient outcomes. Quture's brand is
centered on the value proposition of trust, transparency and
independence. As the free enterprise solution to improving health
and health care while reducing costs, Quture is comprised of a
subsidiary for the operations of its software technology solutions,
plans for a "beyond data" consulting and knowledge applications
company, as well as plans for a personalized, proactive, and
predictive medicine company with a virtual community of members.
These subsidiaries will all be affiliated with the Qx Medical
Exchange, which the Company intends to become the largest medical
and health exchange in the world. Quture International is a Nevada
corporation currently trading under the symbol
TCLN.
QUTURE, INC.
Quture, Inc. is the operations subsidiary of Quture
International, Inc., positioned to become the international
standard in health care performance, outcomes and analytics.
Quture's transformational product QualOptima operates on the
InterSystems technology platform, the leading software platform
globally for health care. QualOptima is the transcendent healthcare
analytics system for performance enhancement to achieve optimal
patient outcomes. The analytics system measures performance against
evidence-based optimal clinical processes of care. The clinical
data repository of QualOptima, the Qualytx integrated aggregate
clinical database, is planned to become the international common
data platform for health and health care. Qualytx will then be
capable of transforming personal health and health care through
knowledge solutions founded on Quture's proprietary science of
knowing what to measure, where that data resides in disparate
databases, using the InterSystems technology to electronically
abstract that data, and converting data to knowledge and actionable
insight with its revolutionary and proprietary analytics system. As
America transitions to payment for value and U.S. and international
pressures converge to measure performance, Quture will navigate the
future of global health and healthcare quality, patient safety and
value.
This release contains forward-looking statements, including,
without limitation, statements concerning our business and possible
or assumed future results of operations. Our actual results could
differ materially from those anticipated in the forward-looking
statements for many reasons including: our ability to continue as a
going concern, adverse economic changes affecting markets we serve;
competition in our markets and industry segments; our timing and
the profitability of entering new markets; greater than expected
costs, customer acceptance of our products or difficulties related
to our integration of the businesses we may acquire; and other
risks and uncertainties as may be detailed from time to time in our
public announcements and SEC filings. Although we believe the
expectations reflected in the forward-looking statements are
reasonable, they relate only to events as of the date on which the
statements are made, and our future results, levels of activity,
performance or achievements may not meet these expectations. We do
not intend to update any of the forward-looking statements after
the date of this document to conform these statements to actual
results or to changes in our expectations, except as required by
law. There is no assurance that a definitive agreement will be
completed.
For Further Information Contact: Contact: Mele
Telitz Director of Communications 303-204-4486 mele@quture.com
Constellation Asset Advisors, Inc. Jens Dalsgaard President +1
(415) 524-8500